July 22, 2026

BSE Limited
Floor 25, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 543271

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051
Trading Symbol: JUBLINGREA

Sub: Press Release and presentation on the financials and operational performance of the Company for the quarter ended June 30, 2026

Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In continuation of our letter dated July 13, 2026, regarding the Investors Conference Call scheduled to be held on Thursday, July 23, 2026, please find enclosed the Press Release and presentation that was discussed during the meeting. The above details will also be available on the website of the Company at www.jubilantingrevia.com.

We request you to take the same on record.

Thanking you,

Yours faithfully,

For **Jubilant Ingrevia Limited**

Deepanjali Gulati
Digitally signed by Deepanjali Gulati
Date: 2026.07.22 14:20:10 +05'30'

Deepanjali Gulati
Company Secretary & Compliance Officer

Encl.: as above

Jubilant Ingrevia Limited
1-A, Sector 16-A,
Noida-201 307, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : U24299UP2019PLC122657

Jubilant Ingrevia Limited
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubilantingrevia.com

PRESS RELEASE

Noida, Wednesday, July 22nd, 2026

JUBILANT INGREVIA LIMITED – Q1'FY27 RESULTS

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Total Revenue	1,038	1,179	**1,300**	10%	*25%*
Total EBITDA	153	172	**209**	22%	*36%*
EBITDA Margin (%)	*15%*	*15%*	***16%***		
PAT after Exceptional Items	75	86	**106**	22%	*41%*
PAT Margin (%)	*7%*	*7%*	***8%***		
Basic and Diluted EPS (Rs.)	*4.7*	*5.5*	***6.7***	*22%*	*41%*

1. *All figures are in Rs Crore unless otherwise stated*

The Board of Jubilant Ingrevia Limited met today to approve financial results for the quarter ended June 30th, 2026.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said:

"We are pleased to report a strong start to FY2027, delivering healthy financial performance in the first quarter. Revenue grew by 25% YoY, while EBITDA increased by 37% YoY, reflecting the strength of our business model and disciplined execution across operations.

Markets Update:

*Despite continued geopolitical uncertainties in the Middle East, demand across the **chemical industry** has remained resilient. Industry volumes have stayed stable, while pricing has shown a firming trend in recent weeks, driven by improving consumption dynamics across key customer segments.*

***Pharmaceuticals** continued to be a key growth driver for the Company, supported by strong volume growth and sustained demand across markets.*

*We witnessed stable momentum in the **Agrochemicals** during the quarter, with demand trends showing encouraging signs of recovery across key segments. Healthy export visibility and improving market dynamics have supported recent price increases.*

*The **Nutrition and Personal Care market** witnessed healthy growth during the quarter, led by higher realizations for Niacinamide and Choline. At the same time, volumes remained resilient across end-use industries, underscoring stable market demand.*

*We are also seeing a **strong traction with customers in electronics/ semicon segment** who are keen to partner with us for integrated opportunities.*

Future Outlook:

*We are encouraged by the progress of our **Pinnacle journey**, which is increasingly reflected in our performance through strong revenue and EBITDA growth and a stronger opportunity pipeline. Supported by sustained volume growth and firmer pricing, we remain confident of continuing our growth momentum. For FY2027, we expect growth to be led by Specialty Chemicals and Nutrition, alongside a recovery in Acetyls. We anticipate sequential improvement in revenue and EBITDA over the coming quarters. The new Multi-Purpose Plant remains on track for commissioning by the end of the current calendar year, further strengthening our CDMO and Fine Chemicals growth roadmap."*

Commenting on the Company's performance, Mr. Deepak Jain, Chief Executive Officer and Managing Director, Jubilant Ingrevia Limited said:

"During the quarter, we continued to advance our strategic priorities while effectively navigating global challenges. Despite disruptions in the Middle East affecting global supply chains and pricing dynamics, our diversified sourcing capabilities, customer relationships and operational agility enabled strong business performance and effective cost pass-through.

The strength of our agile operations and execution capabilities during this challenging period is clearly reflected in our strong Q1 performance.

Let me share the overall Business update for Q1'FY27:

1) *Q1 marked a strong start to the year, with revenue reaching a 15-quarter high of ₹1,300 crore, up 25% YoY, driven by healthy volume growth and improved realizations. EBITDA increased to ₹209 crore, growing 36% YoY and 22% sequentially, while PAT stood at ₹106 crore, up 41% YoY and 22% QoQ.*

2) *Our Speciality Chemical Business, delivered revenue of ₹533 crore, up 11% year-on-year and 3% sequentially, supported by steady business volumes and robust growth in Fine Chemicals and CDMO.*

    a) *Speciality Chemical Business EBITDA stood at ₹139 crore, with margins of 26%, benefiting from improved pricing and a richer product mix led by value-added CDMO and Fine Chemicals offerings.*

    b) *Our Pyridine & Picolines business delivered steady volumes during the quarter. Despite some pricing pressure in Pyridine, cost optimization initiatives helped sustain a healthy performance.*

    c) *Our Fine Chemicals business delivered strong momentum during the quarter. Pyridine and Diketene Derivatives recorded healthy volume growth with improved pricing. In Cosmetics, we now have over 20 products under development and are seeing increasing traction across key personal care segments. In Industrials, we continued to strengthen volumes with existing customers while expanding our new customer pipeline.*

    d) *Our CDMO business continued to gain momentum during the quarter. The Agro segment benefited from the roll Out of big Innovator CDMO volumes, while Pharma saw strong customer traction and a more than threefold expansion in the pipeline following our US and Europe roadshows. In Semiconductors, we are building a dedicated R&D and clean room facility at Greater Noida and are seeing encouraging growth in our opportunity funnel.*

    e) *Our CDMO/Fine Chemicals pipeline continued to show good momentum, we have a funnel of 100+ molecules with ₹3500+ cr peak revenue potential, with now 25+ confirmed molecules which will drive our growth in coming years. We added 5 new molecules in the last quarter across pharma, semicon and personal care segments.*

3) *The Nutrition segment continued its strong momentum, with revenue growing to ₹243 crore, up 36% YoY and 6% QoQ. We achieved the highest EBITDA in the segment over the last three years at ₹36 crore, reflecting a 45% YoY and 12% sequential increase, while margins improved to 15%.*

    a) *In Human Nutrition, Niacinamide volumes grew steadily, supported by strong pricing across food and cosmetics applications. Choline Chloride and CBT pricing also improved on the back of strong customer engagement across key global markets. In Premixes, we strengthened our presence with Tier-1 customers in India following the successful integration of Remidex.*

b) Our Animal Nutrition business delivered a strong performance, supported by significant pricing improvements. Vitamin B3 volumes remained stable, while pricing improved substantially on both a YoY and QoQ basis. In Choline, we maintained our domestic market position and continued to witness healthy demand from Europe, alongside improved customer realizations. The Premixes business also performed well, with volume growth and a favourable product mix driving margin expansion.

4) Chemical intermediates business saw a strong rebound in Q1 on the back of robust demand and price escalations.

a) Revenue in the segment grew to ₹524 crore, up 38% YoY and 21% QoQ, driven by strong volume growth and improved realizations, supported by higher input cost pass-through

b) EBITDA for the segment stood at ₹57 crore, up 240% YoY and 163% QoQ, driven by strong realization gains across the product portfolio and effective cost pass-through.

A quick update on the progress made across our Pinnacle Vision:

1) *On the **Operations and ESG front**, we remain firmly on track, targeting ₹100 crore of lean savings in FY27, we are progressing well on our new MPP plant, and advancing our Supernova program with new GenAI use cases. We successfully cleared over 20 customer quality and EHS audits during the quarter and maintained an exemplary safety record with zero safety incidents across our manufacturing facilities.*
2) *From an **awards and recognition perspective**, we achieved several notable milestones during the quarter. We were certified as a Great Place to Work and ranked among the Top 50 Manufacturing Companies for FY2027. On the safety front, our Gajraula facility earned a Distinction at the British Safety Council International Safety Awards, while our Bharuch and Nira sites were also recognized at the same prestigious platform.*
3) *On the **M&A front**, we successfully completed the integration of Remidex Pharma and are witnessing encouraging traction from Tier-1 human nutrition customers. We are also actively evaluating new growth opportunities across high-potential segments such as Electronics & Semiconductors, Cosmetics, and Nutrition.*
4) *We also hosted a highly interactive Investor & Analyst Day at our Bharuch facility, showcasing our operational strength, pipeline visibility, and growth aspirations. Feedback from the investment community was very encouraging, with the visit reinforcing confidence in our manufacturing capabilities, operational excellence, and expansion potential. Investors also gained deeper conviction in our CDMO growth story, supported by a robust opportunity pipeline and strong commercial traction.*

With a strong start to FY27, we are increasingly confident that our Pinnacle strategy is delivering results. We believe this will be a pivotal year in our journey, providing a strong platform to accelerate growth and create greater value in the quarters ahead."

Q1'FY27 Highlights | Segment Wise Analysis

A. Specialty Chemicals

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Segment Revenue	478	516	533	3%	*11%*
% Share of Overall Revenue	*46%*	*44%*	*41%*		
EBITDA	130	139	139	1%	*7%*
% EBITDA Margin	*27%*	*27%*	*26%*		
% Contribution to EBITDA [2]	*76%*	*72%*	*60%*		

1. *All figures are in Rs Crore unless otherwise stated*
2. *Before adjustment of Unallocated corporate expense/Income*

BUSINESS WISE UPDATES

P&P

- Volumes remained steady across Pyridine & Picolines
- Pricing improved on both QoQ and YoY basis
- Cost rationalization initiatives also yielded positive results

Fine Chemicals

- Pyridine/ Diketene Derivatives: YoY Volume growth across products with pricing improving across the board.
- Cosmetics: 20+ products under development, with growing customer traction across sun care, skin care and hair care segments.
- Industrial: Continued volume traction with existing customers; New customers pipeline being built.

CDMO

- Agro: Stable momentum in the Agro segment, aided by roll out of Agro Innovator CDMO volumes.
- Pharma: Strong pharma customer traction; US & Europe roadshows helped drive a 3x+ pipeline expansion with innovators and Tier-1 CDMOs
- Semicon: Building R&D lab at Gr. Noida with clean room; expansion in funnel across key applications

Business Drivers

- Segment revenue improved YoY, supported by steady volumes across businesses, with Fine Chemicals and CDMO emerging as the key growth drivers.
- EBITDA grew YoY on improved overall pricing, also aided by a higher share of value-added CDMO products and Fine Chemicals offering.

B. Nutrition & Health Solutions

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Segment Revenue	179	230	243	6%	*36%*
% Share of Overall Revenue	17%	20%	19%		
EBITDA	25	32	36	12%	*45%*
% EBITDA Margin	*14%*	*14%*	*15%*		
% Contribution to EBITDA [2]	*14%*	*17%*	*15%*		

1. *All figures are in Rs Crore unless otherwise stated*
2. *Before adjustment of Unallocated corporate expense/Income*

BUSINESS WISE UPDATES

Human Nutrition

- B3: YoY volume growth Niacinamide volumes, with strong improvement in pricing across food and cosmetic end-use segment

- CC/CBT: Pricing improved, supported by strong customer engagement across India, EU and US

- Premixes: Stronger engagement with Tier-1 customers in India post Remidex integration.

Animal Nutrition

- B3: Volumes remaining steady, achieved significant (Higher double digit) Improvement in pricing witnessed over YoY and QoQ both.

- Choline: Maintained domestic market share and sustained EU traction, with improved realizations across customers

- Premixes: Volume growth across products along with favorable product mix leading to improved margins

Business Drivers

- YoY Revenue growth was driven by strong Niacinamide volumes and pricing, supported by a favorable mix of value-added products.

- Margins improved, supported by stronger Niacinamide pricing and increased contribution from the Cosmetics segment

C. Chemical Intermediates Segment

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Segment Revenue	381	433	524	21%	38%
% Share of Overall Revenue	37%	37%	40%		
EBITDA	17	22	57	163%	240%
% EBITDA Margin	4%	5%	11%		
% Contribution to EBITDA [2]	10%	11%	24%		

1. *All figures are in Rs Crore unless otherwise stated*
2. *Before adjustment of Unallocated corporate expense/Income*

BUSINESS WISE UPDATES

Acetic Anhydride

- Steady volumes driven by resilient pharma demand, higher European market share, and stable domestic merchant market share.

- Strong double-digit price growth on both QoQ and YoY basis.

Ethyl Acetate

- Ethyl Acetate volumes recorded strong double-digit YoY growth.

- Double-digit price improvement QoQ and YoY, supported by elevated input costs.

Business Drivers

- Revenue grew both QoQ and YoY, driven by higher volumes and improved realizations, supported by elevated input costs amid Middle East disruptions.

- EBITDA growth was driven by strong QoQ and YoY realization gains across the product portfolio

3. Income Statement – Q1’FY27

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	QoQ	YoY
Revenue from operations					
a) Sales/Income from operations	1029	1166	1289	11%	25%
b) Other operating income	8	13	12	-8%	37%
Total revenue from operations	**1038**	**1179**	**1300**	**10%**	**25%**
Other income	11	9	10	10%	-10%
Total income	**1049**	**1188**	**1310**	**10%**	**25%**
Expenses					
a) Cost of materials consumed	449	597	718	20%	60%
b) Purchases of stock-in-trade	32	44	64	44%	98%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	38	-23	-153	566%	-502%
d) Employee benefits expense	108	106	117	10%	8%
e) Finance costs	13	12	17	48%	37%
f) Depreciation and amortisation expense	41	48	51	5%	25%
g) Other expenses:					
- Power and fuel expense	100	108	138	28%	39%
- Others	168	183	217	19%	29%
Total expenses	**949**	**1076**	**1170**	**9%**	**23%**
Profit before share of loss of an associate (3-4)	100	112	141	26%	41%
Share of loss of an associate	-0.06	-0.02	-0.03		
Exceptional Items	-	-	-		
Profit before tax	**100**	**112**	**141**	**26%**	**41%**
Tax expense					
- Current tax	23	27	43	56%	85%
- Deferred tax charge	2	-2	-8	258%	-628%
Net profit for the period/year	**75**	**86**	**106**	**22%**	**41%**
Earnings per share of ₹ 1 each					
Basic (₹)	*4.7*	*5.5*	*6.7*		
Diluted (₹)	*4.7*	*5.4*	*6.7*		

All figures are in Rs Crore unless otherwise stated

4. Segment P&L – Q1’FY27

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	QoQ (%)	YoY (%)
Revenue					
Speciality Chemicals	478	516	533	3%	11%
Nutrition & Health Solutions	179	230	243	6%	36%
Chemical Intermediates	381	433	524	21%	38%
Total Revenue from Operations	**1,038**	**1,179**	**1,300**	**10%**	**25%**
Reported EBITDA	**153**	**172**	**209**	**22%**	**37%**
Speciality Chemicals	130	139	139	1%	7%
Nutrition & Health Solutions	25	32	36	12%	45%
Chemical Intermediates	17	22	57	163%	240%
Unallocated Corporate & One-Off (Expenses)/Income	-19	-21	-23	-	-
PAT	**75**	**86**	**106**	**22%**	**41%**
EPS	**4.7**	**5.5**	**6.7**	**22%**	**41%**
Reported EBITDA Margins	***15%***	***15%***	***16%***		
Speciality Chemicals	*27%*	*27%*	*26%*		
Nutrition & Health Solutions	*14%*	*14%*	*15%*		
Chemical Intermediates	*4%*	*5%*	*11%*		
Net Margin	***7%***	***7%***	***8%***		

All figures are in Rs Crore unless otherwise stated

About Jubilant Ingrevia Limited

Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to global quality standards and has a broad portfolio of 130+ products.

It has over 45 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50+ plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: www.jubilantingrevia.com.

For more information, please contact:

For Investors

Pavleen Taneja
Jubilant Ingrevia Limited
Ph: +91-120 436 1000
E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media

Sandipan Ghatak
Ph: +919810776182
E-mail: sandipan.ghatak@jubl.com

Sahir Seth
M: +91 9999270119
E-mail: sahir.seth@adfactorspr.com

Earnings Call details: The company will host earnings call at 5.00 PM IST on 23rd July, 2026

Diamond Pass Log-In	
Pre-registration:	To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. DiamondPass™ Click here to ExpressJoin the Call You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.
Conference Dial-In Numbers	
Universal Access:	**+ 91 22 6280 1141**
	+ 91 22 7115 8042
Toll Free Number:	USA: **1 866 746 2133**
	UK: **0 808 101 1573**
	Singapore: **800 101 2045**
	Hong Kong: **800 964 448**

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

INVESTORS
PRESENTATION
Q1’FY 2027

Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

1. The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary
2. Closing Exchange Rate for USD 1 at Rs 94.66 as on June 30, 2026 Rs 94.84 as on March 31, 2026 and Rs 85.76 as on June 30, 2025.

Chairmen’s Message on Q1’FY27 Financial Results

Mr. Shyam S Bhartia
Chairman
&
Mr. Hari S Bhartia
Co-Chairman

“We are pleased to report a strong start to FY2027, delivering healthy financial performance in the first quarter. ***Revenue grew by 25% YoY****, while* ***EBITDA increased by 37% YoY****, reflecting the strength of our business model and disciplined execution across operations.*

Markets Update:

Despite continued geopolitical uncertainties in the Middle East, demand across the ***chemical industry*** *has remained resilient. Industry volumes have stayed stable, while pricing has shown a firming trend in recent weeks, driven by improving consumption dynamics across key customer segments.*

Pharmaceuticals *continued to be a key growth driver for the Company, supported by strong volume growth and sustained demand across markets.*

We witnessed stable momentum in the ***Agrochemicals*** *during the quarter, with demand trends showing encouraging signs of recovery across key segments. Healthy export visibility and improving market dynamics have supported recent price increases.*

The ***Nutrition and Personal Care market*** *witnessed healthy growth during the quarter, led by higher realizations for Niacinamide and Choline. At the same time, volumes remained resilient across end-use industries, underscoring stable market demand.*

We are also seeing a ***strong traction with customers in electronics/ semicon segment*** *who are keen to partner with us for integrated opportunities.*

Future Outlook:

We are encouraged by the progress of our ***Pinnacle journey****, which is increasingly reflected in our performance through strong revenue and EBITDA growth and a stronger opportunity pipeline. Supported by sustained volume growth and firmer pricing, we remain confident of continuing our growth momentum. For FY2027, we expect growth to be led by Specialty Chemicals and Nutrition, alongside a recovery in Acetyls. We anticipate sequential improvement in revenue and EBITDA over the coming quarters. The new Multi-Purpose Plant remains on track for commissioning by the end of the current calendar year, further strengthening our CDMO and Fine Chemicals growth roadmap.”*

Table of Contents

Pinnacle Journey

Pinnacle Journey Recap: We launched our Pinnacle journey almost 2 yrs back with clear priorities and enablers

PINNACLE GROWTH PILLARS

A Specialty Chemicals

Pyridine & Picoline
Retain Global leadership (#1 position, cost leadership) **Scale up Oilfield chemicals**

Fine Chemicals
P&P derivatives: Maintain leadership position
Diketene derivatives: Expand portfolio; Top 3
Cosmetics: Rapid Scale-up; leverage customer/products

CDMO
Pharma & **Agro**: Scape up- Europe/US/Japan
Electronics/ Semi-con: Rapid scale-up; new technologies through partnerships

B Nutrition & Health solutions

Animal Nutrition
Feed Vit B3: Extend global leadership position
Feed Vit B4: Consolidate domestic leadership
Pre-mixes: Leadership in India and neighboring markets

Human Nutrition
Cosmetic/Food grade B3: Rapid Scale-up
Choline Salts: Anchor products for food segment
Foray into Premix / other vitamins

C Chemical Intermediates

Acetic Anhydride
Maintain global leadership position in merchant market
Optimize cost structure

Other Products
(Ethyl Acetate, Acetaldehyde, Bio-Acetic Acid, Propionic Anhydride)
Continue to scale in focused markets/ customers
Optimize cost structure

D ENABLERS

- **Customer-first approach (Key Account Mgmt)**
- **World-class Ops** Best-in-class on **Safety, Quality, ESG**
- **Deep R&D & Tech focus**
- **Digital transformation**
- **Agile Supply Chain**
- **People / Org**

Pinnacle Journey Recap: Created a strong foundation in last 2 years across Pinnacle Growth Pillars and Enablers (1/2)

Customer-first approach

- **KAM Program:** High engagement with top 40 customers; **100+ opportunities in funnel** (25+ already won)
- **Customer roadshows:** EU, US, Japan, **100+ meetings each year**; increased participation in exhibitions/trade shows
- **Launched new verticals:** Semicon, Human Nutrition, Cosmetics/Personal Care, Electronics
- **Expansion in focused markets:** US scale up; Japan/SEA focus; Dedicated BD teams in each market

World-class Operations

- **USFDA plant with zero observations**
- **WEF Lighthouse award (Bharuch)**
- **Dedicated Technology Cell**
- **Multiple new plants constructed (2Kcr deployed)**
- **Lean savings of 100+ Crs/ year**
- **Top tiers in DJSI and Ecovadis**
- **Shift to green power (35% share)**
- **British Safety awards for key sites**
- **Golden Peacock- Quality award**
- **Launch of 5S program for Safety**

Deep R&D and Tech Focus

- **Senior R&D leadership; Expanded R&D team to 150+**
- **50+ products in pipeline; highest # products to be launched in FY27**
- **Dedicated teams for new growth areas: Semicon, Cosmetics, Nutrition**
- **Investment in new technology: Flow, Cryogenic, Semicon purification**
- **Work started on Semiconductor R&D Lab**

Pinnacle Journey Recap: Created a strong foundation in last 2 years across Pinnacle Growth Pillars and Enablers (2/2)

Agile Supply Chain

- **Rejuvenated,** lean team and processes to bring agility and efficiency
- **Digital interventions:** Predictive analytics on key RMs, inventory mgmt., logistics tracking, MRO mgmt., etc.
- **Strategic partnerships and stable contractual arrangements with key suppliers**
- **Navigated price fluctuations** across crude and RM due to Middle East war

Digital

SuperNova program: 50+ Digital/AI initiatives across org, e.g.

- **Launched Gen AI Tool to FastTrack R&D**
- **Smart plants:** Control room, Smart plant; WEF Lighthouse
- **Enabled GenAI across functions:** Legal, Finance, BD
- **Predictive analytics** for RM purchasing, Supplier/ transporter tracking
- **AI Champions across division: SCM, Finance, and Projects work already started**

People/Org

- **Great Place To Work certified** for last two years; amongst top GPTW companies in Manufacturing & Chemicals
- **New and refreshed leadership with new additions across BUs/functions**
- **Verticalised team structure** to bring more focus (high customer centricity)
- **Increased diversity** and dedicated program for Women
- **High performance culture:** Internal talent focus

Our business has become more ‘customer-centric’ with a higher focus on offering solutions across 6 focused end-verticals

Our 3 BUs offer solutions….

Specialty Chemicals

- **Pyridine and Picolines**
- **Fine Chemicals:** P&P and Diketene Derivatives, Cosmetics
- **CDMO:** Agro, Pharma and Semicon

Nutrition

- **Animal Nutrition:** B3, Choline, Premixes
- **Human Nutrition:** B3, CC/CBT, Premixes

Chemical Intermediates

- **Acetic Anhydride**
- **Ethyl Acetate**
- **Acetaldehyde**
- **Bio Acetic Acid**

…across 6 focused verticals

Electronics/Semiconductor Play: Significant progress across key pillars to build an integrated play in future

Product & Pipeline

- **10+ Customers** across EU, US & Japan
- **15+ Products** in pipeline *(Incl. catalogue products E-Pyridine and E-Choline)*
- Multiple products under qualification stage

Technology & Capability

- **Working with external experts** to build capabilities across R&D, Purification etc.
- **Purification technology under development**
- **Strengthening R&D capabilities**

Organisation

- **Set up dedicated team across functions: BD, R&D, Tech, Design**

Infrastructure

- **Set up semiconductor lab at Greater Noida**
- **Clean room facilities under planning**

Industry Events

SEMICON INDIA | SEMICON JAPAN | NEPCON JAPAN R&D and Manufacturing | SEMICON WEST | SEMICON TAIWAN

Witnessing strong customer traction in the Electronics/Semiconductor value chain, with increasing demand for comprehensive end-to-end solutions.

Hosted a very Successful Investor & Analyst Day at our Bharuch Facility on 30th June 2026

Operational Strength | Pipeline Visibility | Growth Confidence

- **Plant visit provided investors and analysts with greater visibility** into Bharuch's manufacturing strength, operational excellence, and expansion potential.
- **Investors gained deeper insight into CDMO's growth potential**, backed by a robust opportunity pipeline and commercial visibility.

Q1’FY27 Highlights

Market Overview Q1'FY27: Volume momentum sustained across segments; realizations remained mixed

- **Demand remains healthy, supported by CDMO opportunities**. Patent expiry opportunities continue to support outsourcing
- **Supply chain disruption has eased**; pricing is stabilizing gradually

- The agrochemical sector continued **volume recovery** supported by demand normalization
- **Pricing/Margins continue to remain under pressure due to competitive intensity (China oversupply)**

- Industrial market **remains mixed with marginal improvement in volumes**
- Margins **remained under pressure with slow down** across sectors; India showed signs of recovery

- The **sector continues to grow** particularly in premium skincare, and cosmetics ingredients
- **Profitability remained stable** with new product portfolios and innovation driving Premiumization and growth

- The nutrition continues to grow with increasing **demand in health supplements, and functional ingredients**
- **Margins improving gradually**, though pricing remains competitive and RM volatility continues



- Electronics/ Semiconductor **market continues volume growth driven by AI, high performing computing**
- **Still in nascent stage; long lead time to scale up**

Several milestones in Q1FY27, building strong pipeline and capabilities for future growth

Business

- **Highest EBITDA in Nutrition over last 3 years;** Highest cosmetic B3 volumes
- **Acetyls Recovery:** Maintained India MS; Increased MS in Europe and product qualified with new customers
- **Specialty:** Continued vol. growth across FC portfolio; Pyridine MS retained despite pricing pressure; CDMO Agro innovator dispatches continues

Customer

- **KAM**: 100+ funnel, 3500Crs+ peak potential
- **5+ new molecules won in Q1**; **25+ molecules confirmed so far**
- **Advanced stage: 10+ molecules, INR ~1100cr** peak revenue

Operations/ ESG

- **FY27 lean savings target of ₹100 Cr on track**
- **New MPP plant progress on track**
- Supernova program on track with new GenAI cases identified
- **20+ Successful quality and EHS audits from key customers**

People / Org

- **Senior Talent additions continue**: R&D, Legal, Projects, Digital and SCM
- **Digitizing journey continues:** Pre-onboarding, New Joiner onboarding, Full and Final settlement

Awards

- **Great place to work certified** for FY27;
- Distinction in the **British Safety Council International Safety Awards (Gajraula)**
- **Bharuch and Nira sites qualified** for the BSC International Safety Awards.

M&A

- **Remidex Pharma**: Completed Integration post acquisition; Good traction from Tier 1 customers
- New opportunities being evaluated across new growth segments: Electronics/ Semicon, Cosmetics, and Nutrition

Financial Results Overview | Q1'FY27 Consolidated

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Total Revenue	1,038	1,179	**1,300**	10%	*25%*
Total EBITDA	153	172	**209**	22%	*36%*
EBITDA Margin (%)	*15%*	*15%*	***16%***		
PAT after Exceptional Items	75	86	**106**	22%	*41%*
PAT Margin (%)	*7%*	*7%*	***8%***		
Basic and Diluted EPS (Rs.)	*4.7*	*5.5*	***6.7***	*22%*	*41%*

- Overall growth driven by both volume expansion and improvement in realizations.
- Speciality Chemicals growth and margins supported by sustained volume growth, with some pressure witnessed on on pyridine pricing.
- Nutrition Business growth was driven by higher volumes, improved pricing, and a favorable product mix
- Chemical Intermediates witnessed healthy growth driven by volumes and improved pricing

Balanced mix of revenues across focused verticals; North America and Europe are scaling up fast

Application wise Split
Q1'FY27



Pharma and Nutrition
are the biggest contributors
with ~51% of revenue

Business wise Split
Q1'FY27



Speciality Chemicals
and Nutrition
contribute >60% of revenues

Geography wise Split
Q1'FY27



North America
& EU
drive >37% of revenue

Achieved Highest Revenue & EBITDA in Last 15+ quarters



Revenue (Rs. Crs)	1075	1020	966	1074	1022	1045	1057	1051	1038	1121	1051	1179	**1300**

EBITDA Trends: Margin growth achieved across all three businesses on YoY basis

Specialty Chemicals

EBITDA (INR Crs)

Y.o.Y Growth 7%
Q.o.Q Growth 0%



- Stable volumes, improved pricing, and the commencement of CDMO shipments to an agro innovator drove YoY EBITDA growth.
- Cost reduction initiatives across Pyridine & Picoline and Fine Chemicals business helped maintain cost leadership

Nutrition

EBITDA (INR Crs)

Y.o.Y Growth 44%
Q.o.Q Growth 13%



- Double digit YoY growth in B3 volumes underpinned overall performance.
- Margin expansion driven by higher price realization across B3 and Choline and favourable product mix

Chemical Intermediates

EBITDA (INR Crs)

Y.o.Y Growth 240%
Q.o.Q Growth 163%



- Maintained market share across key products; Europe market share gain
- Margin expansion was driven by better realizations in Acetic Anhydride and Ethyl Acetate, along with cost optimization initiatives.

% *EBITDA Margins – Before adjustment of Unallocated corporate expense/Income*

Business Segments Overview

Specialty Chemicals | Market, Business & Financial Highlights

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Segment Revenue	478	516	**533**	3%	*11%*
% Share of Overall Revenue	*46%*	*44%*	***41%***		
EBITDA	130	139	**139**	1%	*7%*
% EBITDA Margin	*27%*	*27%*	***26%***		
% Contribution to EBITDA [2]	*76%*	*72%*	***60%***		

Financial Highlights

- Segment revenue improved YoY, **supported by steady volumes across businesses**, with **Fine Chemicals and CDMO emerging as the key growth drivers.**
- EBITDA grew YoY on **improved overall pricing**, also aided by a **higher share of value-added CDMO products and Fine Chemicals offering.**

P&P

- **Volumes remained steady** across **Pyridine & Picolines**
- **Pricing improved** on both QoQ and YoY basis
- **Cost rationalization initiatives** also yielded positive results.

Fine Chemicals

- **Pyridine/ Diketene Derivatives: YoY Volume growth across products** with pricing improving across the board.
- **Cosmetics: 20+ products under development**, with growing customer traction across sun care, skin care and hair care segments.
- **Industrial: Continued volume traction with existing customers**; **New customers pipeline being built.**

CDMO

- **Agro: Stable momentum in the Agro segment, aided by roll out of Agro Innovator CDMO volumes.**
- **Pharma: Strong pharma customer traction**; **US & Europe roadshows helped drive a 3x+ pipeline** expansion with innovators and Tier-1 CDMOs
- **Semicon: Building R&D lab at Gr. Noida with clean room**; expansion in funnel across key applications

1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income

Nutrition & Health Solutions | Market, Business & Financial Highlights

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Segment Revenue	179	230	**243**	6%	*36%*
% Share of Overall Revenue	17%	20%	**19%**		
EBITDA	25	32	**36**	12%	*45%*
% EBITDA Margin	*14%*	*14%*	***15%***		
% Contribution to EBITDA [2]	*14%*	*17%*	***15%***		

Financial Highlights

- YoY Revenue growth was driven by **strong Niacinamide volumes and pricing**, supported by a **favorable mix of value-added products**.
- Margins improved, supported by **stronger Niacinamide pricing** and **increased contribution from the Cosmetics segment**

Human Nutrition

- **B3: YoY volume growth Niacinamide volumes**, with strong improvement **in pricing across food** and cosmetic end-use segment
- **CC/CBT: Pricing improved**, supported by **strong customer engagement across India, EU and US**
- **Premixes: Stronger engagement with Tier-1 customers in India post Remidex integration.**

Animal Nutrition

- **B3: Volumes remaining steady,** achieved significant (Higher double digit) Improvement in pricing witnessed over YoY and QoQ both.
- **Choline:** Maintained domestic market share and sustained EU traction, with **improved realizations across customers**
- **Premixes: Volume growth across products along with favorable product mix leading to improved margins**

1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income

Chemical Intermediates | Market, Business & Financial Highlights

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	Q-o-Q	Y-o-Y
Segment Revenue	381	433	**524**	21%	*38%*
% Share of Overall Revenue	*37%*	*37%*	***40%***		
EBITDA	17	22	**57**	163%	*240%*
% EBITDA Margin	*4%*	*5%*	***11%***		
% Contribution to EBITDA [2]	*10%*	*11%*	***24%***		

Financial Highlights

- **Revenue grew both QoQ and YoY**, driven by **higher volumes and improved realizations**, supported by elevated input costs amid Middle East disruptions.
- EBITDA growth was driven by **strong QoQ and YoY realization gains** across the product portfolio

Acetic Anhydride

- Steady volumes driven by **resilient pharma demand, higher European market share**, and stable domestic merchant market share.
- **Strong double-digit price growth on both QoQ and YoY basis.**

Ethyl Acetate

- **Ethyl Acetate volumes recorded strong double-digit YoY growth.**
- **Double-digit price improvement QoQ and YoY,** supported by elevated input costs.

1) All figures are in Rs Crore unless otherwise stated; 2) Before adjustment of Unallocated corporate expense/Income

Annexures

Annexure I - Income Statement | Consolidated – Q1’FY27

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	QoQ	YoY
Revenue from operations					
a) Sales/Income from operations	1029	1166	1289	11%	25%
b) Other operating income	8	13	12	-8%	37%
Total revenue from operations	**1038**	**1179**	**1300**	**10%**	**25%**
Other income	11	9	10	10%	-10%
Total income	**1049**	**1188**	**1310**	**10%**	**25%**
Expenses					
a) Cost of materials consumed	449	597	718	20%	60%
b) Purchases of stock-in-trade	32	44	64	44%	98%
c) Changes in inventories of finished goods, stock-in-trade and work-in progress	38	-23	-153	566%	-502%
d) Employee benefits expense	108	106	117	10%	8%
e) Finance costs	13	12	17	48%	37%
f) Depreciation and amortisation expense	41	48	51	5%	25%
g) Other expenses:					
- Power and fuel expense	100	108	138	28%	39%
- Others	168	183	217	19%	29%
Total expenses	**949**	**1076**	**1170**	**9%**	**23%**
Profit before share of loss of an associate (3-4)	100	112	141	26%	41%
Share of loss of an associate	-0.06	-0.02	-0.03		
Exceptional Items	-	-	-		
Profit before tax	**100**	**112**	**141**	**26%**	**41%**
Tax expense					
- Current tax	23	27	43	56%	85%
- Deferred tax charge	2	-2	-8	258%	-628%
Net profit for the period/year	**75**	**86**	**106**	**22%**	**41%**
Earnings per share of ₹ 1 each					
Basic (₹)	*4.7*	*5.5*	*6.7*		
Diluted (₹)	*4.7*	*5.4*	*6.7*		

1. All figures are in Rs Crore unless otherwise stated.

Expenses covered in Other expenses include i) Consumption of stores and spares and packing materials. ii) Repairs and maintenance, iii) Freight & forwarding (including ocean freight). iv) Others

Annexure II: Income Statement Segmental – Q1'FY27

Particulars[1]	Q1'FY26	Q4'FY26	Q1'FY27	QoQ (%)	YoY (%)
Revenue					
Speciality Chemicals	478	516	533	3%	11%
Nutrition & Health Solutions	179	230	243	6%	36%
Chemical Intermediates	381	433	524	21%	38%
Total Revenue from Operations	**1,038**	**1,179**	**1,300**	**10%**	**25%**
Reported EBITDA	**153**	**172**	**209**	**22%**	**37%**
Speciality Chemicals	130	139	139	1%	7%
Nutrition & Health Solutions	25	32	36	12%	45%
Chemical Intermediates	17	22	57	163%	240%
Unallocated Corporate & One-Off (Expenses)/Income	-19	-21	-23	-	-
PAT	**75**	**86**	**106**	**22%**	**41%**
EPS	**4.7**	**5.5**	**6.7**	**22%**	**41%**
Reported EBITDA Margins	***15%***	***15%***	***16%***		
Speciality Chemicals	*27%*	*27%*	*26%*		
Nutrition & Health Solutions	*14%*	*14%*	*15%*		
Chemical Intermediates	*4%*	*5%*	*11%*		
Net Margin	***7%***	***7%***	***8%***		

1. *All figures are in Rs Crore unless otherwise stated.*

Annexure III - Conference Call Details

Date : July 23rd, 2026
Time : 05:00 pm IST

Diamond Pass Log-In	
Pre-registration:	To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. 
	You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.
Conference Dial-In Numbers	
Universal Access:	**+ 91 22 6280 1141**
	+ 91 22 7115 8042
Toll Free Number:	USA: **1 866 746 2133**
	UK: **0 808 101 1573**
	Singapore: **800 101 2045**
	Hong Kong: **800 964 448**
Audio Link:	The Audio link will be available on the company website. Please access the link here - https://jubilantingrevia.com/investors/financials/quarterly-results

Thank you for your time

For More Information

Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to global quality standards and has a broad portfolio of 130+ products.

It has over 45 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation.

Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies.

For more information, please visit: www.jubilantingrevia.com

For Investors:

Pavleen Taneja
Jubilant Ingrevia Limited.
☎ Ph: +91 120 436 1000
✉ E-mail: pavleen.taneja@jubl.com

Siddharth Rangnekar, CDR India
☎ Ph: +91 22 6645 1209
✉ E-mail: siddharth@cdr-india.com

For Media:

Sandipan Ghatak
☎ Ph: +91 120 436 1062
✉ E-mail: sandipan.ghatak@jubl.com

Sahir Seth:
☎ Ph: +91 9999270119
✉ E-mail: sahir.seth@adfactorspr.com